Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Breast 2

Conditions

Prostatic Neoplasms 1Myofibroma 1Castration-resistant Prostate Cancer, Advanced Breast Cancer 1Breast Neoplasms 1

Interventions

Docetaxel 390pembrolizumab 326Prednisone 285Gemcitabine 273enzalutamide 256Radiotherapy 251Nivolumab 248Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 198Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 99abiraterone 99cabozantinib 98atezolizumab 97Sorafenib 97Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × LFA102 monoclonal antibody × Genitourinary × Clear all
NCT01338831 2020-12-17

Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer

Novartis

Phase 1 Completed
73 enrolled
BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms, Myofibroma

NCT01610050 2014-11-11

A Phase I Study of LFA102 in Japanese Patients

Novartis

Phase 1 Completed
14 enrolled
BreastGenitourinary

Castration-resistant Prostate Cancer, Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡